| February 1, 2026 |
ERAS |
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors |
Trial Milestone |
Phase 1 |
| February 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| February 2, 2026 |
PCVX |
8-K filed: Other event |
Filing |
— |
| February 2, 2026 |
UTHR |
Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis |
Trial Milestone |
Phase 3 |
| February 2, 2026 |
VTVT |
8-K filed: Material agreement |
Corporate |
— |
| February 2, 2026 |
GNLX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 2, 2026 |
PROK |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 2, 2026 |
CATX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 2, 2026 |
SGMT |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 2, 2026 |
WVE |
8-K filed: Other event |
Filing |
— |
| February 2, 2026 |
LXRX |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| February 2, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
AZN |
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib |
Trial Milestone |
Phase 1 |
| February 3, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
MRK |
Quarterly results filed (8-K) |
Earnings |
— |
| February 3, 2026 |
PFE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 3, 2026 |
AMGN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 3, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| February 3, 2026 |
OCGN |
Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy |
Trial Milestone |
Phase 1/Phase 2 |
| February 3, 2026 |
PHAR |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
REPL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 3, 2026 |
IMVT |
Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease |
Trial Milestone |
Phase 3 |
| February 3, 2026 |
VTRS |
8-K filed: Leadership change |
Corporate |
— |
| February 3, 2026 |
BCYC |
8-K filed: Leadership change |
Corporate |
— |
| February 3, 2026 |
RLAY |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 3, 2026 |
ALT |
8-K filed: Other event |
Filing |
— |
| February 3, 2026 |
KYTX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| February 3, 2026 |
ANGO |
8-K filed: Leadership change |
Corporate |
— |
| February 3, 2026 |
CATX |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 3, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 3, 2026 |
NERV |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 3, 2026 |
AMRX |
8-K filed: Material agreement |
Corporate |
— |
| February 3, 2026 |
RIGL |
8-K filed: Leadership change |
Corporate |
— |
| February 4, 2026 |
MRK |
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study |
Trial Milestone |
Phase 3 |
| February 4, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| February 4, 2026 |
NVS |
6-K filed: Foreign issuer report |
Filing |
— |
| February 4, 2026 |
NVS |
Results filed (20-F) |
Earnings |
— |
| February 4, 2026 |
LLY |
Quarterly results filed (8-K) |
Earnings |
— |
| February 4, 2026 |
GSK |
Results filed (6-K) |
Earnings |
— |
| February 4, 2026 |
ABBV |
Quarterly results filed (8-K) |
Earnings |
— |
| February 4, 2026 |
NVO |
Results filed (20-F) |
Earnings |
— |
| February 4, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 4, 2026 |
VSTM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 4, 2026 |
BSX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 4, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| February 4, 2026 |
MAZE |
8-K filed: Material agreement |
Corporate |
— |
| February 5, 2026 |
BMY |
Quarterly results filed (8-K) |
Earnings |
— |
| February 5, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 5, 2026 |
ABBV |
A Study to Assess Adverse Events and Effectiveness of Intradermally Injected JUVÉDERM® VOLITE™ Gel Filler in Adult Participants For the Improvement of Skin Quality |
Trial Milestone |
Phase 2/Phase 3 |
| February 5, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 5, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 5, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 5, 2026 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 5, 2026 |
ARWR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 5, 2026 |
OCUL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 5, 2026 |
BSX |
8-K filed: Leadership change |
Corporate |
— |
| February 5, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| February 5, 2026 |
LBRX |
8-K filed: Material agreement, Reg FD disclosure, Other event |
Corporate |
— |
| February 5, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 5, 2026 |
IMNN |
8-K filed: Leadership change |
Corporate |
— |
| February 5, 2026 |
MBX |
8-K filed: Other event |
Filing |
— |
| February 5, 2026 |
BEAM |
8-K filed: Leadership change |
Corporate |
— |
| February 5, 2026 |
PBH |
Quarterly results filed (8-K) |
Earnings |
— |
| February 5, 2026 |
LXEO |
8-K filed: Leadership change |
Corporate |
— |
| February 5, 2026 |
SPRB |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 5, 2026 |
ILMN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 6, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 6, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 6, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| February 6, 2026 |
BIIB |
Quarterly results filed (8-K) |
Earnings |
— |
| February 6, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| February 6, 2026 |
IMVT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 6, 2026 |
VTGN |
8-K filed: Listing / standard notice |
Corporate |
— |
| February 6, 2026 |
RNXT |
8-K filed: Leadership change, Other event |
Corporate |
— |
| February 6, 2026 |
TPST |
8-K filed: Material agreement, Acquisition completed, Leadership change |
Corporate |
— |
| February 9, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 9, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 9, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| February 9, 2026 |
OCGN |
8-K filed: Leadership change |
Corporate |
— |
| February 9, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| February 9, 2026 |
RYTM |
A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity |
Trial Milestone |
Phase 2 |
| February 9, 2026 |
SGP |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| February 9, 2026 |
PRQR |
6-K filed: Foreign issuer report |
Filing |
— |
| February 9, 2026 |
BFRI |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 9, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 9, 2026 |
CRIS |
8-K filed: Listing / standard notice |
Corporate |
— |
| February 10, 2026 |
AZN |
Results filed (6-K) |
Earnings |
— |
| February 10, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
TAK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
GILD |
Quarterly results filed (8-K) |
Earnings |
— |
| February 10, 2026 |
INCY |
Quarterly results filed (8-K) |
Earnings |
— |
| February 10, 2026 |
BIIB |
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) |
Trial Milestone |
Phase 2 |
| February 10, 2026 |
EXEL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 10, 2026 |
PRAX |
8-K/A filed: Leadership change |
Corporate |
— |
| February 10, 2026 |
NTLA |
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) |
Trial Milestone |
Phase 3 |
| February 10, 2026 |
RGNX |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 10, 2026 |
NKTR |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 10, 2026 |
NKTR |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 10, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| February 10, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| February 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 11, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 11, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 11, 2026 |
BIIB |
8-K filed: Leadership change, Other event |
Corporate |
— |
| February 11, 2026 |
NBIX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 11, 2026 |
VNDA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 11, 2026 |
AGIO |
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants |
Trial Milestone |
Phase 1 |
| February 11, 2026 |
MRNA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 11, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| February 11, 2026 |
ASND |
Results filed (20-F) |
Earnings |
— |
| February 11, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| February 11, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 11, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 11, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 11, 2026 |
TPST |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 11, 2026 |
OTLK |
8-K filed: Other event |
Filing |
— |
| February 12, 2026 |
SNY |
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis |
Trial Milestone |
Phase 2 |
| February 12, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| February 12, 2026 |
AGIO |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
RARE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
BMRN |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| February 12, 2026 |
ALNY |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
INBS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
ALKS |
8-K filed: Material agreement, Acquisition completed, Reg FD disclosure |
Corporate |
— |
| February 12, 2026 |
INSM |
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) |
Trial Milestone |
Phase 2 |
| February 12, 2026 |
KPTI |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
ANVS |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 12, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
VTGN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 12, 2026 |
GRCE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
BEAM |
8-K filed: Material agreement |
Corporate |
— |
| February 12, 2026 |
CRSP |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
OGN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 12, 2026 |
VRTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 12, 2026 |
SXTP |
8-K filed: Other event |
Filing |
— |
| February 12, 2026 |
WST |
Quarterly results filed (8-K) |
Earnings |
— |
| February 13, 2026 |
NVS |
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies |
Trial Milestone |
Phase 1 |
| February 13, 2026 |
MRNA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 13, 2026 |
ZBIO |
8-K filed: Leadership change |
Corporate |
— |
| February 13, 2026 |
KOD |
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR) |
Trial Milestone |
Phase 3 |
| February 13, 2026 |
CORT |
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH) |
Trial Milestone |
Phase 2 |
| February 13, 2026 |
IMUX |
8-K filed: Material agreement, Leadership change, Other event |
Corporate |
— |
| February 13, 2026 |
NKTR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 13, 2026 |
SGP |
8-K filed: Leadership change |
Corporate |
— |
| February 13, 2026 |
ATNM |
8-K filed: Leadership change |
Corporate |
— |
| February 13, 2026 |
INTS |
8-K filed: Other event |
Filing |
— |
| February 13, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 13, 2026 |
NGEN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 13, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 13, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 13, 2026 |
BCLI |
8-K filed: Material agreement |
Corporate |
— |
| February 13, 2026 |
IRON |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 13, 2026 |
CNSY |
8-K filed: Leadership change |
Corporate |
— |
| February 13, 2026 |
FTH |
8-K filed: Leadership change |
Corporate |
— |
| February 13, 2026 |
DRUG |
6-K filed: Foreign issuer report |
Filing |
— |
| February 15, 2026 |
MANE |
Efficacy and Safety of VDPHL01 in Males With AGA |
Trial Milestone |
Phase 2/Phase 3 |
| February 15, 2026 |
CANF |
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
Trial Milestone |
Phase 3 |
| February 15, 2026 |
ANRO |
Study of ALTO-101 in Patients With Schizophrenia |
Trial Milestone |
Phase 2 |
| February 15, 2026 |
TRAW |
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19 |
Trial Milestone |
Phase 2 |
| February 16, 2026 |
ZBIO |
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis |
Trial Milestone |
Phase 1 |
| February 17, 2026 |
MRK |
A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023) |
Trial Milestone |
Phase 1 |
| February 17, 2026 |
LLY |
A Study of LY4268989 (MORF-057) in Healthy Participants |
Trial Milestone |
Phase 1 |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 17, 2026 |
SNY |
Results filed (20-F) |
Earnings |
— |
| February 17, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
AXSM |
8-K filed: Other event |
Filing |
— |
| February 17, 2026 |
IDYA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
CYTK |
8-K filed: Other event |
Filing |
— |
| February 17, 2026 |
ANNX |
8-K filed: Leadership change |
Corporate |
— |
| February 17, 2026 |
CANF |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
GKOS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
CMPS |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 17, 2026 |
KRYS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
COGT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
AVIR |
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) |
Trial Milestone |
Phase 1 |
| February 17, 2026 |
TTRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 17, 2026 |
HALO |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
IRON |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 17, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
OTLK |
Quarterly results filed (8-K) |
Earnings |
— |
| February 17, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 17, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| February 17, 2026 |
QTTB |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 18, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 18, 2026 |
IBRX |
8-K filed: Other event |
Filing |
— |
| February 18, 2026 |
LPCN |
8-K filed: Other event |
Filing |
— |
| February 18, 2026 |
LPCN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 18, 2026 |
OTLK |
8-K filed: Listing / standard notice |
Corporate |
— |
| February 18, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 18, 2026 |
MBRX |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 18, 2026 |
FTH |
8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure |
Corporate |
— |
| February 19, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 19, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 19, 2026 |
AMGN |
8-K filed: Material agreement |
Corporate |
— |
| February 19, 2026 |
ARGX |
A Study to Assess Adults With CIDP Transitioning From IVIg to Efgartigimod PH20 SC |
Trial Milestone |
Phase 4 |
| February 19, 2026 |
VNDA |
8-K filed: Leadership change |
Corporate |
— |
| February 19, 2026 |
PRAX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
INSM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
MDGL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
CADL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
CORT |
8-K filed: Other event |
Filing |
— |
| February 19, 2026 |
TVTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
CMPS |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| February 19, 2026 |
MDWD |
6-K filed: Foreign issuer report |
Filing |
— |
| February 19, 2026 |
IRD |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
BCAX |
8-K filed: Other event |
Filing |
— |
| February 19, 2026 |
TRAW |
8-K filed: Other event |
Filing |
— |
| February 19, 2026 |
SYRE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
VALN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 19, 2026 |
ARDX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 19, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| February 20, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 20, 2026 |
LLY |
A Study of LY4060874 in Healthy Participants |
Trial Milestone |
Phase 1 |
| February 20, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 20, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 20, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 20, 2026 |
MIRM |
A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) |
Trial Milestone |
Phase 2 |
| February 20, 2026 |
KPTI |
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis |
Trial Milestone |
Phase 3 |
| February 20, 2026 |
IOVA |
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors |
Trial Milestone |
Phase 2 |
| February 20, 2026 |
VTGN |
8-K filed: Leadership change |
Corporate |
— |
| February 20, 2026 |
MNOV |
Quarterly results filed (8-K) |
Earnings |
— |
| February 20, 2026 |
ORMP |
8-K filed: Material agreement |
Corporate |
— |
| February 20, 2026 |
BCTX |
8-K filed: Other event |
Filing |
— |
| February 20, 2026 |
OGN |
8-K filed: Other event |
Filing |
— |
| February 20, 2026 |
MBRX |
8-K filed: Material agreement |
Corporate |
— |
| February 23, 2026 |
AZN |
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC |
Trial Milestone |
Phase 3 |
| February 23, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
JNJ |
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) |
Trial Milestone |
Phase 2 |
| February 23, 2026 |
SNY |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
REGN |
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have |
Trial Milestone |
Phase 2 |
| February 23, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
NVO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
GILD |
8-K filed: Material agreement, Reg FD disclosure |
Corporate |
— |
| February 23, 2026 |
ONC |
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults |
Trial Milestone |
Phase 1 |
| February 23, 2026 |
VNDA |
8-K filed: Other event |
Filing |
— |
| February 23, 2026 |
AAPG |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
RARE |
8-K filed: Other event |
Filing |
— |
| February 23, 2026 |
BMRN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
AXSM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
IBRX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
SMMT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
ASND |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
BSX |
8-K filed: Leadership change, Reg FD disclosure, Other event |
Corporate |
— |
| February 23, 2026 |
VIR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
MLTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
CADL |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 23, 2026 |
NVCR |
LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 2 |
| February 23, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
ABVX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
ORIC |
8-K filed: Other event |
Filing |
— |
| February 23, 2026 |
ORIC |
Quarterly results filed (8-K) |
Earnings |
— |
| February 23, 2026 |
BLRX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
OKYO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
LKFT |
6-K filed: Foreign issuer report |
Filing |
— |
| February 23, 2026 |
ATXI |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 23, 2026 |
GOSS |
8-K filed: Other event |
Filing |
— |
| February 23, 2026 |
GNPX |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
AZN |
Results filed (20-F) |
Earnings |
— |
| February 24, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 24, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 24, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| February 24, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 24, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 24, 2026 |
INCY |
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1) |
Trial Milestone |
Phase 3 |
| February 24, 2026 |
JAZZ |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
CYTK |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
IOVA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
PCVX |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
PCVX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
CORT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
SUPN |
8-K filed: Leadership change |
Corporate |
— |
| February 24, 2026 |
SUPN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
PVLA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
PVLA |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 24, 2026 |
PVLA |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
TARA |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 24, 2026 |
NVCR |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 24, 2026 |
BEAM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
LRMR |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
KNSA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 24, 2026 |
KYTX |
8-K filed: Leadership change, Other event |
Corporate |
— |
| February 24, 2026 |
MAIA |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
ONCY |
8-K filed: Other event |
Filing |
— |
| February 24, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 24, 2026 |
ACIU |
6-K filed: Foreign issuer report |
Filing |
— |
| February 25, 2026 |
AZN |
6-K filed: Foreign issuer report |
Filing |
— |
| February 25, 2026 |
NVS |
Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) |
Trial Milestone |
Phase 2 |
| February 25, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 25, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 25, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 25, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 25, 2026 |
REGN |
ALN-APOC3 in Adult Participants With Dyslipidemia |
Trial Milestone |
Phase 1 |
| February 25, 2026 |
IONS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
RVMD |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
INBS |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 25, 2026 |
MIRM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
ALKS |
8-K filed: Leadership change, Reg FD disclosure |
Corporate |
— |
| February 25, 2026 |
ALKS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
ACAD |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
CLDX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
SRPT |
8-K filed: Leadership change |
Corporate |
— |
| February 25, 2026 |
SRPT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
RCUS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
IMCR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
PTGX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
GERN |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
CRBP |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 25, 2026 |
UTHR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
TLSA |
6-K filed: Foreign issuer report |
Filing |
— |
| February 25, 2026 |
RXRX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 25, 2026 |
TPST |
8-K filed: Reg FD disclosure, Other event |
Filing |
— |
| February 25, 2026 |
CRDL |
6-K filed: Foreign issuer report |
Filing |
— |
| February 25, 2026 |
XNCR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
AZN |
6-K filed: Corporate announcement |
Corporate |
— |
| February 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
GSK |
6-K filed: Clinical or regulatory announcement |
Filing |
— |
| February 26, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
ABBV |
8-K filed: Other event |
Filing |
— |
| February 26, 2026 |
AMGN |
A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic Function |
Trial Milestone |
Phase 1 |
| February 26, 2026 |
INCY |
Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies |
Trial Milestone |
Phase 1 |
| February 26, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
ARGX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
ONC |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
XENE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
TGTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
DFTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
GRFS |
6-K filed: Foreign issuer report |
Filing |
— |
| February 26, 2026 |
NTLA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
BSX |
8-K filed: Material agreement |
Corporate |
— |
| February 26, 2026 |
VIR |
8-K filed: Material agreement |
Corporate |
— |
| February 26, 2026 |
VTRS |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
RYTM |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
PVLA |
8-K filed: Material agreement |
Corporate |
— |
| February 26, 2026 |
LNTH |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
DNLI |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
IMUX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
SNDX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
VCEL |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
NVCR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
DCTH |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
VERA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
EWTX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
PHAT |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
RLAY |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
BCAX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
VTVT |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 26, 2026 |
PCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
NGNE |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 26, 2026 |
PBYI |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
BFRI |
8-K filed: Other event |
Filing |
— |
| February 26, 2026 |
BCRX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
KYMR |
8-K filed: Material agreement, Other event |
Corporate |
— |
| February 26, 2026 |
KYMR |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
WVE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
IRON |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
TRDA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
MNKD |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
FATE |
Quarterly results filed (8-K) |
Earnings |
— |
| February 26, 2026 |
AKBA |
Quarterly results filed (8-K) |
Earnings |
— |
| February 27, 2026 |
GSK |
6-K filed: Corporate announcement |
Corporate |
— |
| February 27, 2026 |
GSK |
6-K filed: Foreign issuer report |
Filing |
— |
| February 27, 2026 |
MRNA |
A Study of Modified mRNA Vaccines in Healthy Adults |
Trial Milestone |
Phase 1 |
| February 27, 2026 |
XENE |
8-K filed: Other event |
Filing |
— |
| February 27, 2026 |
OCUL |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 27, 2026 |
CGON |
Quarterly results filed (8-K) |
Earnings |
— |
| February 27, 2026 |
ALXO |
Quarterly results filed (8-K) |
Earnings |
— |
| February 27, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 27, 2026 |
MESO |
6-K filed: Foreign issuer report |
Filing |
— |
| February 27, 2026 |
MBX |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| February 27, 2026 |
LRMR |
8-K filed: Material agreement |
Corporate |
— |
| February 27, 2026 |
NTHI |
8-K filed: Reg FD disclosure |
Filing |
— |
| February 27, 2026 |
RADX |
6-K filed: Foreign issuer report |
Filing |
— |
| February 27, 2026 |
BCLI |
8-K filed: Material agreement, Leadership change |
Corporate |
— |
| February 27, 2026 |
AMRX |
Quarterly results filed (8-K) |
Earnings |
— |
| February 27, 2026 |
ENSC |
8-K filed: Listing / standard notice |
Corporate |
— |
| February 27, 2026 |
TMCI |
Quarterly results filed (8-K) |
Earnings |
— |
| February 27, 2026 |
ACRV |
8-K filed: Reg FD disclosure |
Filing |
— |